Morgan Stanley raised the firm’s price target on Sight Sciences to $4 from $3 and keeps an Equal Weight rating on the shares. A combination of rising 10 year rates and GLP-1 pressures have pushed the valuation of the U.S. MedTech sector down and given the material de-rating the firm is upgrading its Industry View on MedTech to Attractive, the analyst tells investors. Volumes remain in strong shape, capital equipment is looking healthy and the firm sees limited expected impact from GLP-1s, the analyst added in a note on the group in which the firm adjusted a number of price targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SGHT:
- Sight Sciences price target lowered to $1.80 from $4 at Citi
- Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023
- Disaster for Sight Services (NASDAQ:SGHT): Shares Fall on Medicare Concerns
- Piper says WPS update ‘massive blow’ to Sight Sciences, good news for Glaukos
- Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting